CPIX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
9.1M
-33.2%
13.7M
+65.0%
8.3M
-23.5%
10.8M
-7.5%
11.7M
Cost of Revenue
1.9M
-13.7%
2.2M
+126.7%
988.8K
-50.8%
2.0M
+41.1%
1.4M
Gross Profit
7.2M
-37.1%
11.4M
+56.6%
7.3M
-17.2%
8.8M
-14.2%
10.3M
Operating Expenses
10.3M
-19.4%
12.8M
+38.2%
9.3M
-3.2%
9.6M
+6.4%
9.0M
R&D
1.5M
-5.9%
1.5M
+23.6%
1.3M
-14.6%
1.5M
+13.4%
1.3M
SG&A
7.6M
-25.6%
10.2M
+46.2%
7.0M
-1.3%
7.1M
+6.0%
6.7M
Operating Income
-3129292
-128.2%
-1371202
+30.2%
-1965260
-162.9%
-747478
-157.9%
1.3M
EBITDA
-1853009
-462.7%
-329307
+64.5%
-927456
-423.8%
286.4K
-87.7%
2.3M
Net Income
-3287051
-130.1%
-1428642
+26.7%
-1949046
-165.1%
-735207
-158.9%
1.2M
EPS (Basic)
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
-160.0%
$-0.05
-162.5%
$0.08
EPS (Diluted)
$-0.22
-120.0%
$-0.10
+23.1%
$-0.13
-160.0%
$-0.05
-162.5%
$0.08
Shares (Diluted)
15.0M
+5.1%
14.2M
-4.8%
15.0M
-0.0%
15.0M
-2.0%
15.3M
Cumberland Pharmaceuticals (CPIX) โ€” Financials